Journal Clinical Psychiatry and Cognitive Psychology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal Clinical Psychiatry and Cognitive Psychology (2024) Volume 8, Issue 1

Innovations in Managing Schizophrenia: New Medications and Therapies.

Calabrese Agathokleous *

Department of Psychology, University of Toronto, Toronto, Canada

*Corresponding Author:
Calabrese Agathokleous
Department of Psychology, University of Toronto, Toronto, Canada
E-mail: agathok@torronto.ca

Received: 02-Mar-2024, Manuscript No. AACPCP-24-135141; Editor assigned: 04-Mar-2024, PreQC No. AACPCP-24-135141; Reviewed:16-Mar-2024, QC No. AACPCP-24-135141; Revised:23-Mar-2024, Manuscript No. AACPCP-24-135141 (R); Published:30-Mar-2024, DOI:10.35841/ aatcc -8.1.172

Citation: Agathokleous C. Innovations in Managing Schizophrenia: New Medications and Therapies. J Clin Psychiatry Cog Psychol 2024; 8(1):172

Introduction

Schizophrenia, a chronic and severe mental disorder, affects millions worldwide, presenting challenges in managing symptoms and enhancing quality of life for patients. Historically, treatment options have revolved around antipsychotic medications and various forms of therapy. However, recent years have witnessed significant strides in the development of innovative medications and therapies, promising improved outcomes and better symptom management for individuals grappling with this complex condition [1].

Long-Acting Injectable Antipsychotics (LAIs): LAIs have emerged as a revolutionary option for managing schizophrenia, ensuring medication adherence and consistent therapeutic levels. Newer formulations like paliperidone palmitate and aripiprazole monohydrate offer extended release, reducing dosing frequency and enhancing convenience for patients [2].

Partial Dopamine Agonists: Unlike traditional antipsychotics, which primarily act as dopamine antagonists, partial dopamine agonists like brexpiprazole and cariprazine offer a nuanced approach by modulating dopamine activity. This mechanism potentially minimizes side effects like extrapyramidal symptoms while effectively alleviating psychotic symptoms. Glutamate Modulators: Dysregulation of glutamate neurotransmission is implicated in schizophrenia pathology. Innovative medications targeting glutamate receptors, such as the NMDA receptor modulator, show promise in improving cognitive function and addressing negative symptoms, filling a crucial therapeutic gap [3,4].

Cognitive Remediation Therapy (CRT): CRT aims to enhance cognitive functioning, addressing deficits commonly observed in schizophrenia. Through computer-based exercises and therapist-guided interventions, CRT targets attention, memory, and executive functions, contributing to improved daily functioning and vocational outcomes. Metacognitive Training (MCT):MCT focuses on enhancing patients' awareness and understanding of their cognitive biases and misinterpretations, commonly associated with psychotic experiences. By fostering metacognitive skills, MCT empowers individuals to challenge delusional beliefs and develop more adaptive coping strategies [5].

Integrated Psychological Interventions: Combining elements of cognitive-behavioral therapy (CBT), family therapy, and psychoeducation, integrated psychological interventions provide comprehensive support tailored to the multifaceted needs of individuals with schizophrenia. These approaches promote holistic recovery, addressing symptom management, social integration, and relapse prevention. Digital Therapeutics: Smartphone applications and web-based platforms offer accessible avenues for delivering evidence-based interventions, including cognitive training exercises, mood tracking tools, and psychoeducation modules. Digital therapeutics enhance treatment engagement and monitoring, bridging gaps in traditional healthcare delivery [6,7].

Virtual Reality (VR) Therapy: VR technology provides immersive environments for simulating real-life scenarios and facilitating exposure therapy for individuals with schizophrenia. By gradually exposing patients to feared stimuli in a controlled setting, VR therapy enables desensitization and symptom reduction, particularly in addressing paranoia and social anxiety. While these innovations hold promise in transforming schizophrenia management, several challenges persist. Access to novel medications and therapies remains limited in certain regions, exacerbating disparities in care. Additionally, the integration of new interventions into existing healthcare systems requires concerted efforts in workforce training and infrastructure development [8,9].

Future research endeavors aim to unravel the underlying neurobiological mechanisms of schizophrenia, paving the way for targeted interventions and personalized treatment approaches. Advances in pharmacogenomics offer insights into individual drug responses, facilitating precision medicine initiatives and minimizing adverse effects [10].

Conclusion

Innovations in managing schizophrenia herald a paradigm shift in treatment approaches, emphasizing holistic care and patient-centered interventions. By harnessing advancements in pharmacotherapy, psychotherapy, and digital health technologies, clinicians can better address the diverse needs of individuals living with schizophrenia, fostering recovery, and improving overall well-being.

References

  1. Rahbar Y (2013) East Meets West: Holistic Approach for Treating Serious Mental Illnesses.

    2. Indexed at, Google Scholar

  2. Watkins J. Using medication wisely in treating psychosis. Routledge,199-211.

    3. Indexed at, Google Scholar

  3. Buoey M (2016) The Role of Psychiatric Drugs and their Minimal-Medication Alternatives in the Treatment of Schizophrenia. J Psychiatry, 20(395):2.

    4. Indexed at, Google Scholar, Cross Ref

  4. Bassman L (1997) Holistic mental health care: Alternatives and adjuncts to psychotherapy and medication. Humanist Psychol, 25(2):138-49.

    5. Indexed at, Google Scholar, Cross Ref

  5. Note P (2013) Using medication wisely in treating psychosis. Psychosis.

    6. Indexed at, Google Scholar

  6. Lee MY, Eads R, Yates N, Liu C (2021) Lived experiences of a sustained mental health recovery process without ongoing medication use. Community Ment Health J, 57:540-51.

    7. Indexed at, Google Scholar, Cross Ref

  7. Kane JM, Correll CU (2010) Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry, 71(9):13909.

    8. Indexed at, Google Scholar, Cross Ref

  8. Kane JM, Correll CU (2010) Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci, 12(3):345-57.

    9. Indexed at, Google Scholar, Cross Ref

  9. Lukoff D, Wallace CJ, Liberman RP, Burke K (1986) A holistic program for chronic schizophrenic patients. Schizophr Bull, 12(2):274-82.

    10. Indexed at, Google Scholar, Cross Ref

  10. Thieme A, Wallace J, Meyer TD, Olivier P (2015) Designing for mental wellbeing: towards a more holistic approach in the treatment and prevention of mental illness. British HCI Conference,1-10.

    11. Indexed at, Google Scholar, Cross Ref

Get the App